留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

沙库巴曲缬沙坦在植入埋藏式心律转复除颤器慢性心力衰竭患者中的应用

尚蒙 高晓龙 匡晓晖 张曦 张进 王礼琳

尚蒙, 高晓龙, 匡晓晖, 张曦, 张进, 王礼琳. 沙库巴曲缬沙坦在植入埋藏式心律转复除颤器慢性心力衰竭患者中的应用[J]. 昆明医科大学学报, 2023, 44(11): 63-69. doi: 10.12259/j.issn.2095-610X.S20231109
引用本文: 尚蒙, 高晓龙, 匡晓晖, 张曦, 张进, 王礼琳. 沙库巴曲缬沙坦在植入埋藏式心律转复除颤器慢性心力衰竭患者中的应用[J]. 昆明医科大学学报, 2023, 44(11): 63-69. doi: 10.12259/j.issn.2095-610X.S20231109
Meng SHANG, Xiaolong GAO, Xiaohui KUANG, Xi ZHANG, Jin ZHANG, Lilin WANG. Application of Sacubitril/valsartan in Patients with Chronic Heart Failure Implanted with Implantable Cardioverter Defibrillators[J]. Journal of Kunming Medical University, 2023, 44(11): 63-69. doi: 10.12259/j.issn.2095-610X.S20231109
Citation: Meng SHANG, Xiaolong GAO, Xiaohui KUANG, Xi ZHANG, Jin ZHANG, Lilin WANG. Application of Sacubitril/valsartan in Patients with Chronic Heart Failure Implanted with Implantable Cardioverter Defibrillators[J]. Journal of Kunming Medical University, 2023, 44(11): 63-69. doi: 10.12259/j.issn.2095-610X.S20231109

沙库巴曲缬沙坦在植入埋藏式心律转复除颤器慢性心力衰竭患者中的应用

doi: 10.12259/j.issn.2095-610X.S20231109
基金项目: 国家自然科学基金资助项目(81360039)
详细信息
    作者简介:

    尚蒙(1996~),女,河南镇平人,在读硕士研究生,主要从事心血管疾病临床工作

    通讯作者:

    王礼琳,E-mail:kmwanglin@163.com

  • 中图分类号: R541.6

Application of Sacubitril/valsartan in Patients with Chronic Heart Failure Implanted with Implantable Cardioverter Defibrillators

  • 摘要:   目的  探讨沙库巴曲缬沙坦(S/V)对植入埋藏式心律转复除颤器(ICD)进行心脏性猝死(SCD)一级预防的射血分数下降性的慢性心力衰竭(HFrEF)患者心功能及室性心律失常的影响。  方法  纳入2017年9月至2022年12月期间在云南省第一人民医院心血管内科住院的接受S/V治疗并植入ICD进行SCD一级预防的HFrEF患者。(1)统计患者随访12个月时S/V剂量,治疗3月、6月、12月时心脏彩超指标(LVEF、LVEDD、LAD);(2)ICD记录的室性心律失常事件及治疗情况,动态心电图指标:平均每小时室性早搏次数、全部窦性心搏RR间期的标准差(SDNN)及校正后的平均QT间期(QTc)。  结果  共纳入56例患者。(1)随访1 a时,S/V的平均用药剂量为94.6 mg,bid。(2)随访3月LVEF、LVEDD、LAD均较治疗前改善;随访6月LVEF、LVEDD、LAD较治疗3月时改善;随访12月LVEF、LVEDD、LAD较治疗6月时改善,差异均有统计学意义(P < 0.05)。(3)与随访1~6月相比较,随访7~12月患者室性心动过速/心室颤动(VT/VF)、非持续性室性心动过速(NSVT)、监测室速发作次数均减少,差异有统计学意义(P < 0.05)。(4)与治疗前相比较,随访1 a患者SDNN由(94.38±26.42) ms增加至(102.23±20.36) ms;平均QTc由(441.92±10.64) ms缩短到(411.46±6.00) ms,差异均有统计学意义(P < 0.05)。  结论  (1)植入ICD进行SCD一级预防的HFrEF患者服用S/V治疗的1 a内心脏结构及功能持续改善;(2)随访期间S/V减少了室性心律失常的发生。
  • 表  1  S/V的使用情况[n(%)]

    Table  1.   Usage of S/V[n(%)]

    时间 剂量( mg,bid)
    12.52550100200
    初始 1(1.79) 22(39.29) 26(46.43) 6(10.71) 1(1.79)
    1 a 0(0.00) 2(3.57) 24(42.86) 20(35.71) 10(17.86)
    下载: 导出CSV

    表  2  随访期间LVEF、LVEDD、LAD改善情况表($ \bar x \pm s $

    Table  2.   The improvement of LVEF、LVEDD、LAD during the follow-up period($ \bar x \pm s $

    指标时间数值tP
    LVEF(%) 基线 27.61±5.88
    3月 34.09±7.17 7.666 <0.001*
    6月 38.22±9.46 8.310 <0.001*
    1 a 41.87±10.81 7.408 <0.001*
    LVEDD(cm) 基线 6.91±0.74
    3月 6.38±0.80 −7.838 <0.001*
    6月 6.09±0.81 −5.765 <0.001*
    1 a 5.75±0.83 −9.629 <0.001*
    LAD(cm) 基线 4.36±0.65
    3月 4.15±0.60 −4.630 <0.001*
    6月 3.98±0.59 −4.541 <0.001*
    1 a 3.81±0.57 −5.600 <0.001*
      注:LVEF:左心室射血分数,LVEDD:左心室舒张末期内径,LAD:左房内径,*P < 0.05。
    下载: 导出CSV

    表  3  心律失常事件

    Table  3.   Arrhythmic events

    观察指标1~6月7~12月zP
    VT/VF发作总次数(次/6月) 22 8 −2.325 0.020*
    ≥1次NSVT发作的患者人数(n 21 13 −2.000 0.046*
    NSVT发作总次数(次/6月) 833 168 −3.791 <0.001*
    Monitored VT(>4 beats,次/6月) 115 67 −2.154 0.031*
    PVC(个/h) 13(2,36) 11(0,30) −1.773 0.076
      注:VT/VF:非持续性室性心动过速,VT-Mon:监测室性心动过速,VT/VF: 室性心动过速/心室颤动,PVC:室性期前收缩。*P < 0.05。
    下载: 导出CSV

    表  4  随访1 a与治疗前SDNN与平均QTc比较(ms,$ \bar x \pm s $

    Table  4.   SDNN and mean QTc were compared after 1-year follow-up and before treatment(ms,$ \bar x \pm s $

    时间SDNN平均QTc
    治疗前 94.38±26.42 441.92±10.64
    1 a 102.23±20.36 411.46±6.00
    t 2.328 −3.128
    P 0.031* 0.026*
      注:SDNN:全部窦性心率RR间期的标准差,QTc:校正后的平均QT间期,*P < 0.05。
    下载: 导出CSV
  • [1] Wang H,Chai K,Du M,et al. Prevalence and incidence of heart failure among urban patients in China: A national population-based analysis[J]. Circ Heart Fail,2021,14(10):e008406. doi: 10.1161/CIRCHEARTFAILURE.121.008406
    [2] Murphy S P, Ibrahim N E, Januzzi J L Jr. Heart failure with reduced ejection fraction: A review. [J] JAMA, 2020 , 324(5): 488-504.
    [3] Tsao C W,Lyass A,Enserro D,et al. Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction[J]. JACC Heart Fail,2018,6(8):678-685. doi: 10.1016/j.jchf.2018.03.006
    [4] McMurray J J,Packer M,Desai A S,et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure[J]. N Engl J Med,2014,371(11):993-1004. doi: 10.1056/NEJMoa1409077
    [5] Writing Committee Members; ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA guideline for the management of heart failure[J]. J Card Fail,2022,28(5):e1-e167. doi: 10.1016/j.cardfail.2022.02.010
    [6] Martens P,Nuyens D,Rivero-Ayerza M,et al. Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction[J]. Clin Res Cardiol,2019,108(10):1074-1082. doi: 10.1007/s00392-019-01440-y
    [7] Curtain J P,Jackson A M,Shen L,et al. Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF[J]. Eur J Heart Fail,2022,24(3):551-561. doi: 10.1002/ejhf.2419
    [8] 张常莹,刘晓宇,李晓燕,等. 沙库巴曲缬沙坦对植入了心脏除颤器的心力衰竭患者室性心律失常发生的影响[J]. 中国心脏起搏与心电生理杂志,2021,35(04):305-309. doi: 10.13333/j.cnki.cjcpe.2021.04.005
    [9] El-Battrawy I,Pilsinger C,Liebe V,et al. Impact of sacubitril/valsartan on the long-term incidence of ventricular arrhythmias in chronic heart failure patients[J]. J Clin Med,2019,8(10):1582. doi: 10.3390/jcm8101582
    [10] Vicent L,Juárez M,Martín I,et al. Ventricular arrhythmic storm after initiating sacubitril/valsartan[J]. Cardiology,2018,139(2):119-123. doi: 10.1159/000486410
    [11] Vicent L,Méndez-Zurita F,Viñolas X,et al. Clinical characteristics of patients with sustained ventricular arrhythmias after sacubitril/valsartan initiation[J]. Heart Vessels,2020,35(1):136-142. doi: 10.1007/s00380-019-01454-6
    [12] Vicent L,Martínez-Sellés M. Can sacubitril/valsartan have a proarrhythmic effect in some high-risk patients?[J]. Cardiology,2019,143(1):34-35.
    [13] Yancy C W,Jessup M,Bozkurt B,et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America[J]. J Card Fail,2017,23(8):628-651. doi: 10.1016/j.cardfail.2017.04.014
    [14] Hubers S A,Brown N J. Combined angiotensin receptor antagonism and neprilysininhibition[J]. Circulation,2016,133(11):1115-1124. doi: 10.1161/CIRCULATIONAHA.115.018622
    [15] Levine Y C,Rosenberg M A,Mittleman M,et al. B-type natriuretic peptide is a major predictor of ventricular tachyarrhythmias[J]. Heart Rhythm,2014,11(7):1109-1116. doi: 10.1016/j.hrthm.2014.04.024
    [16] Primessnig U,Deißler P M,Wakula P,et al. Effects of BNP and sacubitrilat/valsartan on atrial functional reserveand arrhythmogenesis in human myocardium[J]. Front Cardiovasc Med,2022,9:859014. doi: 10.3389/fcvm.2022.859014
    [17] Wang Z,Taylor L K,Denney W D,et al. Initiation of ventricular extrasystoles by myocardial stretch in chronically dilated and failing canine left ventricle[J]. Circulation,1994,90(4):2022-2031. doi: 10.1161/01.CIR.90.4.2022
    [18] Sarrias A,Bayes-Genis A. Is sacubitril/valsartan (Also) an antiarrhythmic drug?[J]. Circulation,2018,138(6):551-553. doi: 10.1161/CIRCULATIONAHA.118.034755
    [19] Eiringhaus J,Wünsche C M,Tirilomis P,et al. Sacubitrilat reduces pro-arrhythmogenic sarcoplasmic reticulum Ca2+ leak in human ventricular cardiomyocytes of patients with end-stage heart failure[J]. ESC Heart Fail,2020,7(5):2992-3002. doi: 10.1002/ehf2.12918
    [20] Zhou Y,Rui S,Tang S,et al. Exploration ofmechanisms of sacubitril/ valsartan in the treatment of cardiac arrhythmias using a network pharmacology approach[J]. Front Cardiovasc Med,2022,9:829484. doi: 10.3389/fcvm.2022.829484
    [21] Herring M P,Jacob M L,Suveg C,et al. Feasibility of exercise training for the short-term treatment of generalized anxiety disorder: A randomized controlled trial[J]. Psychother Psychosom,2012,81(1):21-28. doi: 10.1159/000327898
    [22] Bardy G H,Lee K L,Mark D B,et al. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter defibrillator for congestive heart failure[J]. N Engl J Med,2005,352(3):225-237. doi: 10.1056/NEJMoa043399
    [23] Al-Zaiti S S,Pietrasik G,Carey M G,et al. The role of heart rate variability,heart rate turbulence,and deceleration capacity in predicting cause-specific mortality in chronic heart failure[J]. J Electrocardiol,2019,52:70-74. doi: 10.1016/j.jelectrocard.2018.11.006
    [24] Turrini P,Corrado D,Basso C,et al. Dispersion of ventricular depolarization- repolarization: a noninvasive marker for risk stratification in arrhythmogenic right ventricular cardiomyopathy[J]. Circulation,2001,103(25):3075-3080. doi: 10.1161/01.CIR.103.25.3075
    [25] Okin P M,Devereux R B,Howard B V,et al. Assessment of QT interval and QT dispersion for prediction of all-cause and cardiovascular mortality in American Indians: The Strong Heart Study[J]. Circulation,2000,101(1):61-66. doi: 10.1161/01.CIR.101.1.61
    [26] Monzo L,Gaudio C,Cicogna F,et al. Impact of sacubitril/valsartan on implantable defibrillator eligibility in heart failure: a real-world experience[J]. Eur Rev Med Pharmacol Sci,2021,25(18):5690-5700.
    [27] Guerra F,Ammendola E,Ziacchi M,et al. Effect of sacubitril/valsartan on left ventricular ejection fraction and on the potential indication for implantable cardioverter defibrillator in primary prevention: the SAVE-ICD study[J]. Eur J Clin Pharmacol,2021,77(12):1835-1842. doi: 10.1007/s00228-021-03189-8
  • [1] 苏蓉, 林玲, 杨爱玲, 张明国, 李云飞, 梁娅莎.  慢性心力衰竭患者自我管理及社会经济影响研究, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240912
    [2] 邱燕, 王引利, 杨萌萌, 郭良敏, 袁龙会.  肺动脉高压患者MPV、PDW和PCT水平与心功能的关系, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20231219
    [3] 金铭, 岑梅, 赵丽静.  MDT驱动下的路径式SME对CHF患者生活质量的影响, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20221125
    [4] 王艳飞, 马娟, 杨云巧.  沙库巴曲缬沙坦对射血分数降低合并低血压心衰患者的临床疗效及安全性的影响, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20221117
    [5] 吴飞鹏, 郑贤东, 吴琪燕, 洪丽菊, 岳雷, 杨蕊, 陈丹丹, 周友俊.  门控心肌灌注显像与NT-proBNP联合检测对慢性心力衰竭的诊断价值, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220511
    [6] 王海如, 朱平辉, 王军.  运动康复对慢性心力衰竭患者的疗效评价, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220617
    [7] 岑梅, 金铭.  优护+容量自我管理模式对慢性心衰患者生存质量的影响, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20211243
    [8] 张海萍, 杨淑娟, 杨丽霞, 阮兆娟, 郭瑞威.  高同型半胱氨酸对急性心肌梗死合并高血压患者行急诊PCI术后6个月心功能及死亡的影响, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20210319
    [9] 方中, 徐晓东, 王丽华, 张颖, 马超.  eGFR和NT-proBNP对慢性心力衰竭合并房颤患者预后的预测价值, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20211120
    [10] 王维雯, 李德霞, 张杰, 李琳.  射血分数降低的心力衰竭患者血清可溶性ST2与心脏重构的相关性, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20210813
    [11] 岑梅, 袁丹丹, 金铭, 刘雪莲, 尚伟伟.  心脏康复运动对高血压性心脏病心衰患者心功能及日常生活能力的影响, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20210520
    [12] 章体玲, 张伟华, 罗庆祎, 夏洪颖, 鲁一兵.  沙库巴曲缬沙坦治疗扩张型心肌病心力衰竭的疗效, 昆明医科大学学报.
    [13] 朱国富, 全强, 武力勇, 阮志敏, 张明国, 楚天舒.  儿茶酚抑素与慢性心力衰竭的相关性, 昆明医科大学学报.
    [14] 赵新梅, 李俊梅, 杨菊华, 赵存娜, 张佩, 黄晓, 王晓艳, 李海, 张远飞.  网络社交平台对慢性心力衰竭居家患者延伸护理的作用, 昆明医科大学学报.
    [15] 杜自宏, 孙勇.  256层螺旋CT评估主动脉夹层患者动脉弹性、左心功能及其相关性, 昆明医科大学学报.
    [16] 蔡仁慧, 赵新湘.  心梗后心肌瘢痕的DE-MRI检测及其与室性心律失常关系的研究现状, 昆明医科大学学报.
    [17] 罗永丽.  心脏康复对老年慢性心力衰竭患者安全性的临床评价, 昆明医科大学学报.
    [18] 王煜.  性激素水平与老年慢性心衰患者心功能的关系, 昆明医科大学学报.
    [19] 郝应禄.  三维电标测指导下室性心律失常的射频消融治疗临床研究, 昆明医科大学学报.
    [20] 曲美他嗪治疗陈旧性心肌梗死合并难治性心力衰竭临床疗效观察, 昆明医科大学学报.
  • 加载中
计量
  • 文章访问数:  1142
  • HTML全文浏览量:  740
  • PDF下载量:  5
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-08-22
  • 网络出版日期:  2023-11-09
  • 刊出日期:  2023-11-30

目录

    /

    返回文章
    返回